Latest:
Dr. Heimberger on the Variability of Responses in Glioblastoma
Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Amy Duffield, MD, PhD
Latest:
Dr. Duffield on Implications for Immunotherapy in Nasopharyngeal Carcinoma
Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.
Amy P. Abernethy, MD, PhD
Latest:
Dr. Abernethy Discusses Anamorelin as a Treatment Option for Patients with Cancer Anorexia-Cachexia
Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.
Amy R. Lipson, PhD
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry Data
Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
Amy Sebastian-Deutsch, RN, DNP, CNS, APN, AOCNS
Latest:
Oncology Nurse Navigators and Community Health Workers: Building Unique Relationships for Cancer Care, Part II of II
Amy Sebastian-Deutsch describes the potential for a collaborative relationship between Oncology Nurse Navigators and community health workers.
Ana Acuna-Villaorduna, MD
Latest:
Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses
Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.
Ana M. Gonzalez-Angulo, MD
Latest:
Triple Receptor-Negative Breast Cancer: Current and Future Treatments
Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.
Ana Oaknin, MD
Latest:
Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer
Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.
Ana Stojanovska, BS
Latest:
NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management
Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of
available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial
relationship between payers and oncologists through a collaborative model.
Anand B. Karnad, MD
Latest:
Cancer Disparities Heighten Need to Recruit Hispanics for Clinical Trials
The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities
Anas Al-Janadi, MD
Latest:
Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report
This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Anastasios Raptis, MD
Latest:
Dr. Raptis on DRd in Newly Diagnosed Multiple Myeloma
Anastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.